Effects of Lipid Emulsions in Parenteral Nutrition of Esophageal Cancer Surgical Patients Receiving Enteral Nutrition:  A Comparative Analysis

Wang, Wuping; Yan, Xiaolong; Ni, Yicheng; Guo, Kang; Chen, Ke; Cheng, Qi; Lü, Qiang; Li, Xiaofei

doi:10.3390/nu6010111

Cited by 9 publications

(10 citation statements)

References 38 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of two studies reporting on total bilirubin, one reported that olive oil-based ILE significantly decreased total bilirubin levels from baseline, whereas the other reported no change; however, the levels were within normal limits [ 38 , 71 ]. Similar findings for liver function tests have been reported for severely malnourished adult patients [ 73 ], adult patients receiving long-term PN [ 39 , 90 ], adult patients with esophageal cancer [ 92 ], and adult patients with severe burns [ 35 ].…”

Section: Liver Functionsupporting

confidence: 80%

“…We identified 24 studies [ 20 , 33 , 35 , 38 , 39 , 41 , 43 , 44 , 45 , 46 , 51 , 61 , 64 , 71 , 72 , 73 , 75 , 85 , 87 , 88 , 89 , 90 , 91 , 92 , 93 ] and three meta-analyses [ 66 , 81 , 83 ] that investigated the effects of olive oil-based ILE on liver function ( Table 5 ). Findings have varied across studies, and no clear pattern of effect of olive oil-based ILE on markers of liver function (sometimes called liver function tests) such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin (total or conjugated) or on biliary tract function markers such as alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (GGT) have been discerned.…”

Section: Liver Functionmentioning

confidence: 99%

See 1 more Smart Citation

Biological and Clinical Aspects of an Olive Oil-Based Lipid Emulsion—A Review

Cai¹,

Calder

Cury-Boaventura

et al. 2018

Nutrients

View full text Add to dashboard Cite

Intravenous lipid emulsions (ILEs) have been an integral component of parenteral nutrition for more than 50 years. Numerous formulations are available and are based on vegetable (soybean, olive, coconut) and animal (fish) oils. Therefore, each of these formulations has a unique fatty acid composition that offers both benefits and limitations. As clinical experience and our understanding of the effects of fatty acids on various physiological processes has grown, there is evidence to suggest that some ILEs may have benefits compared with others. Current evidence suggests that olive oil-based ILE may preserve immune, hepatobiliary, and endothelial cell function, and may reduce lipid peroxidation and plasma lipid levels. There is good evidence from a large randomized controlled study to support a benefit of olive oil-based ILE over soybean oil-based ILE on reducing infections in critically ill patients. At present there is limited evidence to demonstrate a benefit of olive oil-based ILE over other ILEs on glucose metabolism, and few data exist to demonstrate a benefit on clinical outcomes such as hospital or intensive care unit stay, duration of mechanical ventilation, or mortality. We review the current research and clinical evidence supporting the potential positive biological and clinical aspects of olive oil-based ILE and conclude that olive oil-based ILE is well tolerated and provides effective nutritional support to various PN-requiring patient populations. Olive oil-based ILE appears to support the innate immune system, is associated with fewer infections, induces less lipid peroxidation, and is not associated with increased hepatobiliary or lipid disturbances. These data would suggest that olive oil-based ILE is a valuable option in various PN-requiring patient populations.

show abstract

Section: Liver Functionsupporting

confidence: 80%

Section: Liver Functionmentioning

confidence: 99%

Biological and Clinical Aspects of an Olive Oil-Based Lipid Emulsion—A Review

Cai¹,

Calder

Cury-Boaventura

et al. 2018

Nutrients

View full text Add to dashboard Cite

show abstract

“…We grouped the published studies into three groups (Table 1) [34567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606263646566676869707172737475767778798081]. The first group included studies that identified the characteristics of hosts exhibiting inflammation, the second group included studies that measured the effect of treatment interventions, and the third group included studies that predicted the outcomes of interventions.…”

Section: Factors Associated With Inflammation In Patients With Cancermentioning

confidence: 99%

“…Historically, laboratory values are used to assess the inflammatory status of the patients (Table 2) [317232634353839424450596266697173747576777879848687888990919293949596979899100101102103104105106]. Laboratory parameters are economical to evaluate, easily measurable, repeatable, and ready to use in daily clinical practice.…”

Section: Approaches For Evaluating Inflammatory Parametersmentioning

confidence: 99%

“…Assessment of immune cells and cytokines is necessary to evaluate the immune response in patients (Table 3) [131314182022252729303134353942434447505152535460636772798081858687889091939597103116117118119120121122123124125126127128129130131132]. The innate immune response is rapid and does not require prior exposure to an antigen.…”

Section: Approaches For Evaluating Inflammatory Parametersmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for Evaluating the Inflammation Status in Patients with Cancer

Güner

Kim

2019

J Gastric Cancer

View full text Add to dashboard Cite

Inflammation can be a causative factor for carcinogenesis or can result from a consequence of cancer progression. Moreover, cancer therapeutic interventions can also induce an inflammatory response. Various inflammatory parameters are used to assess the inflammatory status during cancer treatment. It is important to select the most optimal biomarker among these parameters. Additionally, suitable biomarkers must be examined if there are no known parameters. We briefly reviewed the published literature for the use of inflammatory parameters in the treatment of patients with cancer. Most studies on inflammation evaluated the correlation between host characteristics, effect of interventions, and clinical outcomes. Additionally, the levels of C-reactive protein, albumin, lymphocytes, and platelets were the most commonly used laboratory parameters, either independently or in combination with other laboratory parameters and clinical characteristics. Furthermore, the immune parameters are classically examined using flow cytometry, immunohistochemical staining, and enzymelinked immunosorbent assay techniques. However, gene expression profiling can aid in assessing the overall peri-interventional immune status. The checklists of guidelines, such as STAndards for Reporting of Diagnostic accuracy and REporting recommendations for tumor MARKer prognostic studies should be considered when designing studies to investigate the inflammatory parameters. Finally, the data should be interpreted after adjusting for clinically important variables, such as age and cancer stage.

show abstract